I keep comparing two retatrutide numbers: the Phase 2 efficacy-estimand result of 24.2% mean weight reduction at 48 weeks, and the company-reported Phase 3 results saying up to 28.7%, not yet peer-reviewed. Then I look at completed CTgov trials and see enrollments of 32, 46, and 445, while the larger CTgov trials enrolled 1946 and 2335.
Is the 28.7% actually comparable to the 24.2%, or are different populations and missing-data rules doing a lot of work here? I'm tracking trial methodology more than my own fasting glucose and lipids right now.